【肺癌】「eyonis™ LCS」: 肺癌篩檢AI在RELIVE關鍵研究中被證實具有療效和安全性

 【肺癌】「eyonis™ LCS」: 肺癌篩檢AI在RELIVE關鍵研究中被證實具有療效和安全性

 文章出處  

Businesswire 

 

 原文標題  

eyonis™ LCS, Median Technologies’ AI-Powered Software as a Medical Device for Lung Cancer Screening, Confirmed Efficacy and Safety in RELIVE Pivotal Study 

 

 Twitter  

https://x.com/aimedadviser/status/1907232087373222378 

 

 文章序號  

7654 

 

智醫科學－AI醫療技術、應用與市場動態

Copyright ©2025 智醫科學 MEDai.tw All rights reserved.

The content of this site is intended for healthcare and medical professionals.